BridgeBio Pharma, Inc. — Earnings Quality Grade F
BBIO · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO surged by 94 days (8 → 101)
AR growth 2853.1% exceeds revenue growth 126.3%
Revenue grew 126.3% but CFFO only 14.4%
Expense Quality
Insufficient data
CapEx growth 7.7% vs revenue 126.3%. Normal
SG&A/Gross Profit = 110.4%, exceeds 70%
Gross margin 95.8%, change -2.4pp. Stable
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
FCF is negative ($-0.5B)
Accruals ratio = -29.8%. Low accruals
Cash $0.6B covers only 32% of debt $1.9B
Balance Sheet Health
No goodwill. Clean balance sheet
Interest coverage = -2.8x (<2x). Financial stress
Other assets -8.2% vs revenue 126.3%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
No goodwill
Manipulation Score
M-Score = 8.22 (> -1.78). LIKELY MANIPULATOR
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25